NEW YORK, June 13, 2017 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Roche Holding AG (“Roche” or the “Company”) (otcmkts:RHHBY). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether Roche and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here to join a class action]
On June 5, 2017, Roche issued a press release reporting results from a recent trial of the drugs Herceptin and Perjeta in combination as a breast cancer treatment, advising investors that the combination treatment offered only a slight benefit compared to treatment by Herceptin alone.
On this news, Roche’s American Depositary Receipt price fell $1.76, or 5.12%, to close at $32.61 on June 5, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-roche-holding-ag–rhhby-300473514.html
SOURCE Pomerantz LLP
Copyright (C) 2017 PR Newswire. All rights reserved